| Title |
New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil
|
|---|---|
| Published in |
Integrated Blood Pressure Control, March 2012
|
| DOI | 10.2147/ibpc.s13784 |
| Pubmed ID | |
| Authors |
Massimo Volpe, Carmine Savoia |
| Abstract |
Renin-angiotensin-system (RAS) activation plays a key role in the development of hypertension and cardiovascular disease. Drugs that antagonize the RAS (angiotensin-converting enzyme [ACE] inhibitors and angiotensin receptor blockers [ARBs]) have proven clinical efficacy in reducing blood pressure values and cardiovascular morbidity and mortality. ACE inhibitors partially inhibit plasma ACE, and angiotensin II generation. Thus, ARBs, which block selectively type 1 angiotensin II receptor (AT(1)R), have been developed and used in the clinical management of hypertension and cardiovascular disease. Experimental and clinical trials with ARBs indicate that this class of drug represents an effective, safe and well tolerated therapeutic option for the prevention and care of hypertension, even though there is no proven superiority as compared to ACE inhibitors except for the better tolerability. Most ARBs may not completely inhibit the AT(1)R at the approved clinical doses. Azilsartan medoxomil is a newly approved ARB for the management of hypertension. This ARB induces a potent and long-lasting antihypertensive effect and may have cardioprotective properties. This article reviews the current evidence on the clinical effectiveness of azilsartan in hypertension. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 13 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 1 | 8% |
| Unknown | 12 | 92% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 3 | 23% |
| Researcher | 3 | 23% |
| Student > Ph. D. Student | 2 | 15% |
| Professor | 1 | 8% |
| Student > Doctoral Student | 1 | 8% |
| Other | 2 | 15% |
| Unknown | 1 | 8% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 62% |
| Agricultural and Biological Sciences | 1 | 8% |
| Biochemistry, Genetics and Molecular Biology | 1 | 8% |
| Immunology and Microbiology | 1 | 8% |
| Chemistry | 1 | 8% |
| Other | 0 | 0% |
| Unknown | 1 | 8% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 April 2012.
All research outputs
#15,305,492
of 25,584,565 outputs
Outputs from Integrated Blood Pressure Control
#45
of 74 outputs
Outputs of similar age
#98,267
of 168,428 outputs
Outputs of similar age from Integrated Blood Pressure Control
#1
of 1 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 38th percentile – i.e., 38% of other outputs scored the same or lower than it.
So far Altmetric has tracked 74 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.5. This one is in the 40th percentile – i.e., 40% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 168,428 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them